Quotables
"We live in a society exquisitely dependent on science and technology, in which hardly anyone knows anything about science and technology."
Carl Sagan
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7538214 | 2-(poly-substituted aryl)-6-amino-5-halo-4-pyrimidinecarboxylic acids and their use as herbicides 6-Amino-5-halo-4-pyrimidinecarboxylic acids having poly-substituted aryl substituents in the 2-position, and their amine and acid derivatives, are potent herbicides demonstrating a broad spectrum of weed control. ... | 05/26/2009 |
| 7439240 | Purine-or pyrrolol[2,3-d]pyrimidine-2-carbonitiles for treating diseases associated with cysteine protease activity The present invention therefore provides a compound of formula (I) and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases ... | 10/21/2008 |
| 7419984 | Pyrimidines and uses thereof The invention relates to pyrimidines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor-cells. ... | 09/02/2008 |
| 7375108 | 2-substituted pyrimidines The invention relates to 2-substituted pyrimidines of the formula I in which the index n and the substituents R1 to R3 and L are as defined in the description and R4 corresponds... | 05/20/2008 |
| 7332491 | Dihydropteridione derivatives, process for their manufacture and their use as medicament Disclosed are new dihydropteridinones of general formula (I) whereby the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specificat... | 02/19/2008 |
| 7326705 | Heterocyclic sodium/proton exchange inhibitors and method Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, al... | 02/05/2008 |
| 7312359 | Tetralin and indane derivatives and uses thereof Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R2 are as defined herein. Also provided are methods f... | 12/25/2007 |
| 7300907 | 2-(Poly-substituted aryl)-6-amino-5-halo-4-pyrimidinecarboxylic acids and their use as herbicides 6-Amino-5-halo-4-pyrimidinecarboxylic acids having poly-substituted aryl substituents in the 2-position, and their amine and acid derivatives, are potent herbicides demonstrating a broad spectrum of weed control. ... | 11/27/2007 |
| 7294627 | Chemical compounds Compounds of formula (I) in which R1, R2, R3 and R4, have the meanings given in the specification are Factor Xa inhibitors useful in the treatment of thrombotic disorde... | 11/13/2007 |
| 7253174 | N-heterocyclic inhibitors of TNF-α expression N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharm... | 08/07/2007 |
| 7129239 | Purine compounds and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. ... | 10/31/2006 |
| 7125997 | Differential tumor cytotoxicity compounds and compositions The invention is directed to novel biaryl derivatives, to the uses of these compounds in various medicinal applications, including the treatment, prevention and control of proliferative diseases such as tumors, and to pharmaceutical compositions comprising these com... | 10/24/2006 |
| 7112589 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases The invention provides compounds of formula I or a pharmaceutically acceptable salt or ester thereof (I), wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions ... | 09/26/2006 |
| 7053089 | N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for relieving pain. ... | 05/30/2006 |
| 7041670 | Florfenicol-type antibiotics The present invention relates to novel florfenicol compounds having the chemical structure: wherein the compounds are useful for the treatment and/or prevention of bacterial infections in a broad range of patients such... | 05/09/2006 |
| 7034019 | Prodrugs of HIV replication inhibiting pyrimidines The present invention concerns compounds of formula (A1)(A2)N—R1 (I),the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and stereochemically isomeric forms thereof, wherein R1 is sub... | 04/25/2006 |
| RE39056 | 4-Azasteroids for treatment of hyperandrogenic conditions Compounds of structural Formula (I) and pharmacologically acceptable salts and esters thereof possess 5α-reductase inhibitory activity. These compounds inhibit 5α-reductase type 1 and type 2. The compounds of structural Formula... | 04/04/2006 |
| 7005433 | Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su... | 02/28/2006 |
| 6992187 | Process for the preparation of birthonectin receptor antagonists A process for the preparation of a compound of the formula wherein the substituents are defined as in the specification. ... | 01/31/2006 |
| 6953802 | Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, su... | 10/11/2005 |
| 6916804 | Pyrimidine A2b selective antagonist compounds, their synthesis and use The subject invention provides compounds having the structure: wherein R1 is substituted or unsubstituted phenyl or a 5-6 membered heterocyclic or heteroaromatic ring containing from 1 to 5 heteroatoms; R | 07/12/2005 |
| 6906067 | N-heterocyclic inhibitors of TNF-α expression N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutica... | 06/14/2005 |
| 6906076 | Compounds and methods of use to treat infectious diseases The present invention concerns alkyl aryl carbonyl compounds that possess anti-infective activity. The compounds of the invention can be used to target specific nuclear localization signal, thereby blocking importation of specific proteins or molecular complex into ... | 06/14/2005 |
| 6846828 | Aminopyrimidine and aminopyridine anti-inflammation agents Aminopyrimidine and aminopyridine (I) compounds, compositions and methods useful in the treatment of inflammatory, metabolic or malignant conditions, are provided herein. ... | 01/25/2005 |
| 6844347 | Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same The invention relates to compounds of formula I, in which R1, R2, R3 and R4 have the meanings given in the claims. Said compounds are valuable active ingredients for the trea... | 01/18/2005 |
| 6838128 | High polarization dopants for ferroelectric liquid crystal compositions The invention relates to chiral nonracemic liquid crystal compounds which are useful as components in liquid crystal compositions to impart high polarization to the mixture. The materials of this invention can be combined with liquid crystal host materials to impart... | 01/04/2005 |
| 6838464 | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compos... | 01/04/2005 |
| 6797714 | Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists This invention is related to novel carboxyl substituted chroman derivatives which are useful in the treatment of beta-3 receptor mediated conditions. ... | 09/28/2004 |
| 6756380 | 5-phenyl-pyrimidine derivatives Compounds of the general formula are described: wherein R1 is hydrogen or halogen; R2 is hydrogen, halogen, lower alkyl or lower alkoxy; R3 is halogen, trifluoromethy... | 06/29/2004 |
| 6734187 | Purine derivatives and medicaments comprising the same as active ingredient Purine derivatives represented by the following formula and salts thereof: wherein R1 represents a C1-C4 alkyl group or difluoromethyl group; R2 represents tetrahydrofuranyl gr... | 05/11/2004 |
| 6716850 | Non-nucleoside reverse transcriptase inhibitors Compounds of the formula I: where; R1 is O, S; R2 is an optionally substituted nitrogen-containing heterocycle, wherein the nitrogen is located at the 2 position relative to the (thio)... | 04/06/2004 |
| 6680385 | Catalytic preparation of aryl methyl ketones using a molecular oxygen-containing gas as the oxidant A method for the preparation of aryl methyl ketones converts a variety of ethyl arenas to the corresponding aryl methyl ketones using a dioxygen-containing gas as the oxidant. The catalyst used for the reaction is a metal complex bearing general formulas ... | 01/20/2004 |
| 6657060 | Pyrimidine derivatives Pyrimidine derivatives have been found to be useful as neuropeptide Y receptor ligands and particularly as antagonists. These pyrimidine derivatives may be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, diabe... | 12/02/2003 |
| 6645968 | Potassium channel openers Compounds of formula I: ##STR1## are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.... | 11/11/2003 |
| 6635766 | Process for the preparation of arylamides of heteroaromatic carboxylic acids A process for the preparation of arylamides of heteroaromatic carboxylic acids of the formula: ##STR1## in which each An is nitrogen or CRn (n=1 to 5), with the proviso that at least one of the ring members is nitrogen and that two n... | 10/21/2003 |
| 6632820 | Pyrimidine compounds ##STR1## A pyrimidine derivative of formula (I) wherein, for example, R1 is-(1-6C)alkyl or (3-5C)alkenyl [optionally substituted by a phenyl substituent]; Q1 and Q2 are independently selected from phenyl, naphthyl, indanyl... | 10/14/2003 |
| 6620817 | [5-CHLORO-6-PHENYL-2-(4-TRIFLUOROMETHYLPHENYL)-4-PYRIMIDINYLAMINO]ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATE OF THESE COMPOUNDS A [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinyl-amino]acetami de derivative of the formula (I): ##STR1## wherein R1 is a methyl group or a cyclopropyl group, and a pharmaceutical composition containing the same. Said compound... | 09/16/2003 |
| 6610846 | Heteroaromatic glucokinase activators 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secret... | 08/26/2003 |
| 6589947 | Use of corticotropin releasing factor antagonists and related compositions The present invention relates to compositions and methods of achieving a therapeutic effect including, the treatment or prevention of Syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a corticotropin relea... | 07/08/2003 |
| 6518425 | Method of manufacture of 1,3-oxathiolane nucleosides Processes for the preparation of 1,3-oxathiolane nucleosides are provided that include efficient methods for the preparation of the 1,3-oxathiolane ring and subsequent condensation of the 1,3-oxathiolane with a pyrimidine or purine base. Using the process... | 02/11/2003 |
